查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363983

2023-2030年全球呼吸道合胞病毒診斷市場

Global Respiratory Syncytial Virus Diagnostic Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

預計全球呼吸道合胞病毒診斷市場在預測期內（2023-2030年）年複合成長率將達到6.5%。呼吸系統疾病發病率上升、新生兒數量增加、體外診斷需求不斷成長以及對護理設施的需求不斷成長是推動市場擴張的幾個主要原因。根據美國國立衛生研究院 (NIH) 2022 年 11 月發布的報告，90.0% 的兒童在生命的頭兩年內感染 RSV，成人和年齡較大的兒童經常再次感染 RSV。大多數 RSV 患者會出現上呼吸道疾病，但相當一部分人也會出現下呼吸道疾病，主要是細支氣管炎。例如，2023年7月，美國批准阿斯特捷利康和賽諾菲生產的Beyfortus（nirsevimab）用於治療新生兒、嬰兒和24個月以下兒童的呼吸道合胞病毒（RSV）下呼吸道疾病（LRTD）在第一個RSV 季節期間或剛開始時出生。

細分市場前景

全球呼吸道合胞病毒診斷市場按產品、方法和最終用戶細分。根據產品，市場細分為試劑盒和檢測以及儀器。根據方法，市場細分為快速抗原檢測、分子診斷、直接螢光抗體方法、免疫測定等。此外，根據最終用戶，市場分為醫院、診所和實驗室。在這些產品中，由於針對呼吸道合胞病毒的基於螢光焦點的高通量微中和測試的開發不斷增加，預計試劑盒和檢測細分市場將佔據相當大的市場佔有率。

預計分子診斷細分市場將在全球呼吸道合胞病毒診斷市場中佔據相當大的佔有率

其中，分子診斷細分領域預計將在全球呼吸道合胞病毒診斷市場中佔據相當大的佔有率。細分市場的成長歸因於慢性病對全球人口的影響日益增加；預計呼吸道疾病將會頻繁增加。預計這也將增加市場對檢測 RSV 等傳染病的分子診斷的需求。例如，2021 年 3 月，GENETWORx Labs 宣布了一項診斷測試，該測試將所有三種不同呼吸道病毒（Flu AB、COVID-19 和 RSV）的早期識別結合到一個針對患者的測試樣本中。 TCA/GENETWORx Flu AB/COVID 組合檢測是一種分子診斷 PCR 檢測，可識別甲型和乙型流感病毒，並將其與 RSV 和引起 COVID-19 的 SARS-CoV-2 病毒區分開來。它還可以檢測兩種類型的流感病毒：甲型流感病毒和乙型流感病毒。

區域展望

全球呼吸道合胞病毒診斷市場根據地理位置進一步細分，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國） 、日本、韓國和亞洲其他地區）以及世界其他地區（中東和非洲以及拉丁美洲）。其中，由於該地區呼吸道合胞病毒感染負擔增加，預計亞太地區將在全球市場中佔據顯著佔有率。投資、技術開發、產品批准和推出、政府努力以及主要市場參與者採取的其他主要策略的增加。主要參與者包括Jacobson Pharma、Ascletis Pharma Inc.、Nuance Pharma、Sino Bioogical Inc.、VedaLab等。

預計北美在全球呼吸道合胞病毒診斷市場中將以顯著的年複合成長率成長

在所有地區中，北美地區預計在預測期內將以相當大的年複合成長率成長。區域成長歸因於生物和奈米技術 (PCR) 等現代方法的發展，有助於開發 RSV 檢測技術，包括蛋白質印跡、酶聯免疫吸附試驗 (ELISA)、直接免疫螢光和即時聚合酶鏈反應。此外，許多國家的政府組織為研發計劃提供資金，以創造新的治療方法。臨床疫苗研究數量的增加、體外診斷需求的增加、小兒肺炎盛行率的增加以及分子​​診斷使用的增加是預計推動市場的其他因素。這些都是推動該地區市場擴張的具體因素。

與其他程序相比，快速抗原測試的有效性、增加產品推出以及重要的政府和市場參與者活動都預計將促進區域成長。由於嬰兒和幼兒RSV感染的發生率較高。根據美國國家過敏和傳染病研究所（NIAID）2022年7月發布的報告，據估計，RSV感染每年導致美國65歲以上成年人1.4萬人死亡。據認為，RSV 每年影響全球 6,400 萬人，並導致全球 16 萬人死亡。分子方法具有極高的特異性、內部檢查和快速的周轉時間，因此前景廣闊。與患者群體中的免疫測定相比，分子診斷在該地區的應用越來越廣泛。

目錄

第 1 章：報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 按細分
    • 按地區

第 2 章：市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • Becton, Dickinson and Company
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • BioMerieux SA
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • F. Hoffmann-La Roche Ltd.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場細分

  • 按產品分類的全球呼吸道合胞病毒診斷市場
    • 試劑盒和檢測
    • 儀器
  • 按方法分類的全球呼吸道合胞病毒診斷市場
    • 快速抗原檢測測試
    • 分子診斷
    • 直接螢光抗體法
    • 免疫測定
    • 其他（流式細胞儀）
  • 最終用戶的全球呼吸道合胞病毒診斷市場
    • 醫院
    • 診所
    • 實驗室

第 5 章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第 6 章：公司簡介

  • Abbott Laboratories
  • Beckman Coulter Inc.
  • BioCartis, Hologic, Inc
  • Bio-Rad Laboratories, Inc.
  • CorisBioConcept
  • Danaher
  • DiaSorin Molecular LLC.
  • Fast Track Diagnostics Luxembourg S.a R.L.
  • Luminex Corp.
  • Merck KGaA
  • NorgenBiotek Corp.
  • Ortho Clinical Diagnostics
  • Quest Diagnostics
  • QuidelOrtho Corporation
  • Siemens Healthcare Diagnostics Inc.
  • Virax Biolabs
Product Code: OMR2027690

Title: Global Respiratory Syncytial Virus Diagnostic Market Size, Share & Trends Analysis Report by Product (Kits and Assays, Instruments), by Method (Rapid Antigen Detection Tests, Molecular Diagnostics, Direct Fluorescent Antibody Method, Immunoassays and Others), and by End-Users (Hospitals, Clinics, and Laboratories),Forecast Period (2023-2030).

The global respiratory syncytial virus diagnostic market is anticipated to grow at a significant CAGR of 6.5% during the forecast period (2023-2030). Rising incidence rates of respiratory illnesses, increasing newborn populations, an expanding need for in-vitro diagnostics, and rising demand for point-of-care facilities are a few of the main reasons propelling market expansion. According to a National Institute of Health (NIH) report published in November 2022, 90.0% of children get RSV within the first two years of life, and adults and older children frequently get it again. The majority of RSV patients will experience upper respiratory sickness, but a sizeable proportion will also experience lower respiratory illness, primarily bronchiolitis. For instance, in July 2023, US approved Beyfortus (nirsevimab), Manufactured by AstraZeneca and Sanofi, for the treatment of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns, infants, and children up to 24 months old who were born during or just beginning their first RSV season.

Segmental Outlook

The global respiratory syncytial virus diagnostic market is segmented on the product, method, and end-users. Based on the product, the market is sub-segmented into kits and assays, and instruments. Based on the method, the market is sub-segmented into rapid antigen detection tests, molecular diagnostics, direct fluorescent antibody methods, immunoassays, and others. Further, on the basis of end-users, the market is sub-segmented into hospitals, clinics, and laboratories. Among the products, the kits and assay sub-segment is anticipated to hold a considerable share of the market owing to the increase in the development of a fluorescent focus-based, high-throughput microneutralization test for the respiratory syncytial virus.

The Molecular Diagnostics Sub-Segment is Anticipated to Hold a Considerable Share of the Global Respiratory Syncytial Virus Diagnostic Market

Among the methods, the molecular diagnostics sub-segment is expected to hold a considerable share of the global respiratory syncytical virus diagnosis market. The segmental growth is attributed to the increasing impact of chronic diseases on the global population; respiratory illnesses are projected to grow frequently. This is also anticipated to increase demand for molecular diagnostics in the market for testing infectious diseases like RSV. For instance, in March 2021, GENETWORx Labs announced a diagnostic test that combines the early identification of all three distinct respiratory viruses-Flu A-B, COVID-19, and RSV-in a single test sample for patients. The TCA/GENETWORx Flu A-B/COVID Combo Test is a molecular diagnostic PCR test that identifies influenza A and B viruses and distinguishes them from RSV and SARS-CoV-2, the virus that causes COVID-19. It also detects two types of influenza viruses, influenza A and B.

Regional Outlook

The global respiratory syncytial virus diagnostic market is further segmented based on geography, including North America (the US and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the increased burden of respiratory syncytial virus infections in the region. Rise in investments, technical development, product approvals and launches, government efforts, and other major strategies taken by the key market participants. The key players include Jacobson Pharma, Ascletis Pharma Inc., Nuance Pharma, Sino BioogicalInc.,VedaLab and others.

The North America is Anticipated to Grow at a Significant CAGR in the Global Respiratory Syncytial Virus Diagnostic Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to development of modern methods like bio- and nanotechnology (PCR) are helping to develop RSV detection technologies including the western blot, enzyme-linked immunosorbent test (ELISA), direct immunofluorescence, and real-time polymerase chain reaction. In addition, government organizations from many nations provide funding for R&D initiatives to create new treatments. A rise in the number of clinical vaccine studies, an increase in the need for in-vitro diagnostics, an increase in the prevalence of pediatric pneumonia, and a rise in the use of molecular diagnostics are additional factors anticipated to propel the market. These are the specific factors driving market expansion in the region.

Rapid antigen test effectiveness compared to other procedures, increasing product introductions, and significant government and market participant activities are all anticipated to enhance regional growth. Owing to the higher occurrence of RSV infections in babies and young children. According to National Institute of Allergy and Infectious Disease (NIAID), report published in July 2022, According to estimates, RSV infection cause 14,000 death in US adults over 65 each year. RSV is thought to affect 64 million people globally each year, and cause death of 160,000 people globally. With their great specificity, internal checks, and rapid turnaround times, molecular approaches hold promise. Compared to immunoassays in the patient group, molecular diagnostics are becoming more widely used in the region.

Market Players Outlook

The major companies serving the respiratory syncytial virus includes diagnostic market Abbott Laboratories, Bio-Rad Laboratories, Inc., DiaSorin Molecular LLC., NorgenBiotek Corp., Siemens Healthcare Diagnostics Inc. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in February 2021, BARDA and Luminex Corp. collaborate on a single, rapid diagnostic test to distinguish coronavirus from influenza and RSV infections. With the help of this grant from BARDA, Luminex Corporation will be able to complete the development work necessary to submit an application to the FDA for Emergency Use Authorization (EUA) of the ARIES Flu A/B & RSV+SARS-CoV-2 Assay and to get 510(k) clearance for this combo test.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global respiratory syncytial virus diagnostic market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Becton, Dickinson and Company
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. BioMerieux SA
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. F. Hoffmann-La Roche Ltd.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Respiratory Syncytial Virus Diagnostic Market by Product
    • 4.1.1. Kits and Assays
    • 4.1.2. Instruments
  • 4.2. Global Respiratory Syncytial Virus Diagnostic Market by Method
    • 4.2.1. Rapid Antigen Detection Tests
    • 4.2.2. Molecular Diagnostics
    • 4.2.3. Direct Fluorescent Antibody Method
    • 4.2.4. Immunoassays
    • 4.2.5. Others (Flow Cytometry)
  • 4.3. Global Respiratory Syncytial Virus Diagnostic Market by End-Users
    • 4.3.1. Hospitals
    • 4.3.2. Clinics
    • 4.3.3. Laboratories

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Abbott Laboratories
  • 6.2. Beckman Coulter Inc.
  • 6.3. BioCartis, Hologic, Inc
  • 6.4. Bio-Rad Laboratories, Inc.
  • 6.5. CorisBioConcept
  • 6.6. Danaher
  • 6.7. DiaSorin Molecular LLC.
  • 6.8. Fast Track Diagnostics Luxembourg S.a R.L.
  • 6.9. Luminex Corp.
  • 6.10. Merck KGaA
  • 6.11. NorgenBiotek Corp.
  • 6.12. Ortho Clinical Diagnostics
  • 6.13. Quest Diagnostics
  • 6.14. QuidelOrtho Corporation
  • 6.15. Siemens Healthcare Diagnostics Inc.
  • 6.16. Virax Biolabs

LIST OF TABLES

  • 1. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 2. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC KITS AND ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC INSTRUMRNT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
  • 5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA RAPID ANTIGEN DETECTION TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA DIRECT FLUORESCENT ANTIBODY METHOD MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA IMMUNOASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL OTHERS RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)
  • 11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. NORTH AMERICAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)
  • 19. EUROPEAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 20. EUROPEAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 21. EUROPEAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
  • 22. EUROPEAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)
  • 23. ASIA- PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 24. ASIA- PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 25. ASIA- PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
  • 26. ASIA- PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)
  • 27. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PROUCT, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022 VS 2030 (%)
  • 2. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC KITS AND ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC INSTRUMRNT MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022 VS 2030 (%)
  • 5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA RAPID ANTIGEN DETECTION TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA DIRECT FLUORESCENT ANTIBODY METHOD MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA IMMUNOASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL OTHERS RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022 VS 2030 (%)
  • 11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. US RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. CANADA RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. UK RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. FRANCE RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. GERMANY RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. ITALY RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. SPAIN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. REST OF EUROPE RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. INDIA RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. CHINA RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. JAPAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. SOUTH KOREA RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)